Neurovalens

United States

Wellness & Lifestyle Therapeutics Healthy Living

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges!Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier. Awards:Winner: Health Category at the Future Planet Awards 2019Winner: Best New Concept or Innovation at the 2018 Yahoo Sports Technology Awards Winner: 2018 CES Innovation AwardWinner: Start-Up of the Year at the 2018 Digital DNA AwardsWinner: Start-Up World Cup Northern Ireland Winner 2018Winner: Randox Health Weight Management Product of the Year 2018Winner: Business Eye Small Business Awards Healthcare Business of the Year 2018Winner: Innovative Business of the Year at the BEFTA 2018 awards Placed 3rd at 2018 CES Last Gadget StandingFinalist for Med Tech Innovator AwardFinalist in the Best Investment in the Disruptive Tech category at the UK Business Angel Investment Awards 2019

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Neurovalens on @MedStartr Today #WeightLoss #ObesityOverweight #WeightManagement #WellnessLifestyle #Therapeutics #HealthyLiving #MedMo #MedStartrVentures

https://www.medstartr.ai/s/sH5IFKMzXuA

Get Involved in Neurovalens

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2013
Website: neurovalens.com/

Disease Areas

Weight Loss Obesity & Overweight Weight Management

Technologies

NeurotechnologyNeuromodulation

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Neurovalens?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.